newsfilter
← Latest News
PR Newswire·

Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026

JNJ
  • Johnson & Johnson announced 24 abstracts featuring clinical data and real-world evidence across its neuropsychiatry portfolio for presentation at the 2026 Psych Congress Annual Meeting in New Orleans from September 15-19.
  • New pivotal Phase 3 data will be presented evaluating the efficacy and safety of CAPLYTA (lumateperone) in the acute treatment of manic episodes in bipolar I disorder.
  • Additional CAPLYTA data covering bipolar depression and major depressive disorder (MDD) will highlight the asset's breadth across mood disorders, including metabolic outcomes and patient subgroups.
  • New real-world evidence will be shared regarding CAPLYTA treatment patterns, dosing, and duration for patients with bipolar depression in routine clinical practice.
  • Analyses of SPRAVATO (esketamine) nasal spray will focus on real-world evidence regarding its impact on treating anhedonia, a core depression symptom linked to poorer outcomes.
  • Phase 3 clinical trial data for seltorexant in adults with MDD and insomnia symptoms will be presented, alongside real-world insights into disease burden and treatment outcomes for this population.
  • Real-world studies on Long-Acting Injectables (LAIs) will evaluate schizophrenia-related hospitalizations in young dual-eligible patients prior to initiation and subsequent relapse risks, as well as treatment satisfaction.
  • CAPLYTA is an oral atypical antipsychotic approved for MDD, schizophrenia, and bipolar depression, with a supplemental New Drug Application recently approved for delayed time to relapse in schizophrenia.
  • SPRAVATO is an NMDA receptor antagonist approved for treatment-resistant depression and MDD with acute suicidal ideation, having been administered to over 250,000 patients globally.
  • Johnson & Johnson's LAI portfolio includes INVEGA SUSTENNA (monthly), INVEGA TRINZA (3-month), and INVEGA HAFYERA (6-month) for schizophrenia treatment.
  • Seltorexant is an investigational first-in-class selective antagonist of the orexin-2 receptor being developed as an adjunctive treatment for MDD with insomnia.
  • Important safety warnings for CAPLYTA, INVEGA LAIs, and SPRAVATO include risks of increased mortality in elderly patients with dementia-related psychosis, suicidal thoughts in young patients, metabolic changes, and specific administration protocols.